EN IT

Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers to improve the clinical management of cancer patients by creating innovative diagnostic tools that may allow a personalized treatment.

Latest Product Literature

Characterization of SCCA-IgM as a biomarker of liver disease in an Asian cohort of patients. Scand J Clin Lab Invest. ePub:1-7. 2018.

Low levels of squamous cell carcinoma antigen–IgM complexes in serum are predictors of better survival in patients with liver cirrhosis. Dig Liver Dis. 50(S1):42. 2018.

Serum and bile squamous cell carcinoma antigen detection: a new prognostic marker in patients with perihilar cholangiocarcinoma. Dig Liver Dis. 50(S1):40. 2018.

Role of SERPINB3 like serological and molecular biomarker into NASH development and progression. Dig Liver Dis. 50(S1):18. 2018.

Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society. EuroBiotech J. 2(1):30-34. 2018.

The protease-inhibitor SerpinB3 outlines a stem-like subset in human cholangiocarcinoma. Dig Liver Dis. 50(S1):47. 2018.


Press Releases

Youtube

Tweets by Xeptagen